Review

Tetanus: A Review

Authors: Peter Ataro, MD, David Mushatt, MD, MPH&TM, FIDSA, Shagufta Ahsan, MD

Abstract

Tetanus is a preventable illness occurring worldwide with a high mortality, mostly affecting neonates in developing countries. Effects are toxin mediated and the diagnosis is clinical. Antibiotics, antitoxin, immunoglobulin and wound care are the mainstays of management.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Centers for Disease Control and Prevention tetanus surveillance-United States, 2001-2008. MMWR Morb Mortal Wkly Rep 2011;60:365-369.
 
2. Hsu S, Groleau G. Tetanus in the emergency department: a current review. J Emerg Med 2001;20:357-365.
 
3. Biological products. Bacterial vaccines and toxoids; implementation of efficacy review; proposed rule.Fed Regist 1985;50:51002-51117.
 
4. Simonsen O, Bentzon M, Heron I. ELISA for the routine determination of antitoxic immunity to tetanus. J Biol Stand 1986;14:231-239.
 
5. Borrow R, Balmer P, Roper MH. Tetanus update 2006. In: Immunization, Vaccines and Biologicals (Immunological Basis for Immunization Series; Module 3). Geneva: World Health Organization; 2006: 1-35.
 
6. Tetanus: questions and answers information about the disease and vaccines: immunization Action Coalition. St Paul, MN. Available at: www.vaccineinformation.org; www.immunize.org. Accessed April 20, 2011.
 
7. Bardenheier B, Prevots DR, Khetsuriani N, et al. Tetanus surveillance-United States, 1995-1997. CDC surveillance summaries (July 3). MMWR Morb Mortal Wkly Rep 1998;47(no. SS-2):1-13.
 
8. Centers for Disease Control and Prevention. Tetanus surveillance-United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2003;52(SS03);1-8.
 
9. Backer EL, Gregory P, Jaén CR, et al. A closer look at adult female health care maintenance visits. Fam Med 2006;38:355-360.
 
10. Nowalk MP, Zimmerman RK, Cleary SM, et al. Missed opportunities to vaccinate older adults in primary care. J Am Board Fam Pract 2005;18:20-27.
 
11. Tetanus cases in US from 1947-2005. In: Tetanus and Tetanus Toxoid: Epidemiology and Prevention of Vaccine-Preventable Diseases. Atlanta, GA: National Immunization Program, Centers for Disease Control and Prevention; 2006.
12. Talan DA, Abrahamian FM, Moran GJ, et al. Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. Ann Emerg Med 2004;43:305-314.
13. Mandell GL, Bennett JE, Dolin R. Mandell. Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA, Churchill Livingstone/Elsevier, 2010.
14. Bleck TP, Brauner JS. Tetanus. In: Scheld WM, Whitely RJ, Durack DT, eds. Infections of the Central Nervous System. 2nd ed. Philadelphia, PA, Lippincott-Raven, 1997:629-653.
15. Schwartz E, Rodeisperger E. Skin and soft tissue infections, in Schillinger D, Harwood-Nuss A, eds. Infections in Emergency Medicine. New York, Churchill Livingstone, 1990, vol 2, pp 63-113.
16. Kerr J. Current topics in tetanus. Intensive Care Med 1979;5:105-110.PubMed | CrossRef
17. Erdmann G, Wiegand H, Wellhoner HH. Intraaxonal and extraaxonal transport of 125I-tetanus toxin in early local tetanus. Naunyn Schmiedebergs Arch Pharmacol 1975;290:357-373.
18. Trujillo MH, Castillo A, Espana J, et al. Impact of intensive care management of the prognosis of tetanus. Chest 1987;92:63-65.
19. Wright DK, Lalloo UG, Nayiager S, et al. Autonomic nervous system dysfunction in severe tetanus: current perspectives. Crit Care Med 1989;17:371-375.
20. Edlich RF, Silloway KA, Haines PC, et al. Tetanus. Compr Ther 1986;12:12-21.
21. Benett J, Azhar N, Rahim F, et al. Further observations on ghee as a risk factor for neonatal tetanus. Int J Epidemiol 1995;24:643-647.
22. Parashar UD, Bennett JV, Boring JR, et al. Topical antimicrobials applied to the umbilical cord stump: a new intervention against neonatal tetanus. Int J Epidemiol 1998;27:904-908.
23. Bennett JV, Schooley M, Traverso HP, et al. A newly identified risk factor for neonatal tetanus: implications for global control. Int J Epidemiol 1996:25:879-884.
24. Tetanus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book. 11th ed. Atlanta, GA: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention; 2009:273-282.
25. Shannon MW, Borron SW, Burns MJ, et al. Winchester's Clinical Management of Poisoning and Drug Overdose. 4th ed. Philadelphia, PA: Saunders/Elsevier; 2007.
26. Abrutyn E. Tetanus. In: Kasper DL, Fauci AS, Longo DL, et al, eds. Harrison's Infectious Diseases (Specialty Series 17th Edition.). New York: McGraw-Hill Inc, 2010, pp 429-434.
27. Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J (Clin Res Ed) 1985;291:648-650.
28. Yen LM, Dao LM, Day NPJ, et al. Management of tetanus: a comparison of penicillin and metronidazole. Presented at the Symposium of Antimicrobial Resistance in Southern Vietnam. Ho Chi Minh City, Vietnam; 1997.
29. Blake P, Feldman R, Buchanan T, et al. Serologic therapy of tetanus in the United States, 1965-1971. JAMA 1976;235:42-44.
30. Attygalle D, Rodrigo N. Magnesium sulphate for control of spasms in severe tetanus. Can we avoid sedation and artificial ventilation? Anaesthesia 1997;52:956-962.
31. Attygalle D, Rodrigo N. Magnesium sulphate for control of spasms in severe tetanus. Anesthesia1999;54:302-303.
32. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 5th ed. Philadelphia, PA: Saunders/Elsevier; 2008:805-839.
33. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years-United States, 2011. MMWR Morb Mortal Wkly Rep 2011;60:3.
34. Recommended adult immunization schedule: United States, 2009*. Ann Intern Med 2009;150:40-44.
35. Passen E, Andersen B. Clinical tetanus despite a protective level of toxin-neutralizing antibody. JAMA 1986;255:1171-1173.
36. Abrahamian F, Pollack CJ, LoVecchio F, et al. Fatal tetanus in a drug abuser with "protective" antitetanus antibodies. J Emerg Med 2000;18:189-193.
37. Reed DB, Westneat SC. Exposure risks and tetanus immunization status in farmers ages 50 and over. South Med J 2009:102:251-252.
38. Heath CW Jr, Zusman J, Sherman IL. Tetanus in the United States 1950 to 1960. Am J Public Health 1964:54;769-779.